NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free CRMD Stock Alerts $5.19 -0.14 (-2.63%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$5.11▼$5.4150-Day Range$3.24▼$6.3952-Week Range$2.57▼$7.00Volume736,959 shsAverage Volume552,582 shsMarket Capitalization$284.46 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get CorMedix alerts: Email Address CorMedix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside150.5% Upside$13.00 Price TargetShort InterestBearish17.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 5 Articles This WeekInsider TradingAcquiring Shares$50,718 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.50 out of 5 starsMedical Sector676th out of 907 stocksPharmaceutical Preparations Industry309th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.11% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently increased by 13.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRMD. Previous Next 2.9 News and Social Media Coverage News SentimentCorMedix has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for CorMedix this week, compared to 2 articles on an average week.Search Interest12 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows6 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,718.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.83) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About CorMedix Stock (NASDAQ:CRMD)CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More CRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRMD Stock News HeadlinesApril 20, 2024 | investing.comCorMedix product 'DefenCath' gains CMS transitional payment statusApril 20, 2024 | finanznachrichten.deCorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCathApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 19, 2024 | marketwatch.comCorMedix Shares Rise 6% After DefenCath Meets Payment CriteriaApril 19, 2024 | globenewswire.comCorMedix Inc. Announces CMS Grants TDAPA to DefenCathApril 18, 2024 | americanbankingnews.comCorMedix Inc. (NASDAQ:CRMD) Short Interest Up 6.2% in MarchApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | globenewswire.comCorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 15, 2024 | finance.yahoo.comCRMD Apr 2024 7.000 callApril 15, 2024 | finance.yahoo.comCRMD Apr 2024 8.000 putApril 11, 2024 | finance.yahoo.comCorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America ConferenceApril 11, 2024 | globenewswire.comCorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America ConferenceApril 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)April 8, 2024 | globenewswire.comCorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLCApril 2, 2024 | finance.yahoo.comBreakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD)March 27, 2024 | finance.yahoo.comCorMedix Inc. to Present at the Needham Annual Healthcare ConferenceMarch 16, 2024 | finance.yahoo.comCRMD Apr 2024 6.000 putMarch 16, 2024 | finance.yahoo.comCRMD Apr 2024 3.000 putMarch 16, 2024 | finance.yahoo.comCRMD Apr 2024 3.000 callMarch 13, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)March 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)March 13, 2024 | finance.yahoo.comCorMedix Inc. (NASDAQ:CRMD) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | seekingalpha.comAyr Wellness reports mixed Q4 results; initiates Q1 FY24 outlookMarch 12, 2024 | markets.businessinsider.comBuy Rating on Cormedix Amidst DefenCath Launch and Strong Financial PositioningMarch 12, 2024 | marketwatch.comCorMedix Shares Move Lower After 4Q UpdateMarch 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), PROCEPT BioRobotics (PRCT)See More Headlines Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRMD CUSIPN/A CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees82Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$19.00 Low Stock Price Target$9.00 Potential Upside/Downside+149.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,340,000.00 Net MarginsN/A Pretax Margin-132,646.69% Return on Equity-72.31% Return on Assets-63.97% Debt Debt-to-Equity RatioN/A Current Ratio6.97 Quick Ratio6.78 Sales & Book Value Annual Sales$60,000.00 Price / Sales4,759.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book4.07Miscellaneous Outstanding Shares54,810,000Free Float52,839,000Market Cap$285.56 million OptionableOptionable Beta1.86 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Joseph Todisco MBA (Age 47)CEO & Director Comp: $1.07MDr. Matthew T. David M.D. (Age 45)Executive VP & CFO Comp: $597.27kMs. Erin Mistry (Age 41)Executive VP & Chief Commercial Officer Comp: $561.57kMs. Elizabeth Masson-Hurlburt B.A. (Age 44)Executive VP and Chief Clinical Strategy & Operations Officer Comp: $538.91kMs. Kaufman Beth Zelnick Esq.Executive VP, Chief Legal Officer & Corporate SecretaryDonna UcciSenior VP & Head of Global QualityDr. Tushar MukherjeeSenior VP & Head of Technical OperationsMore ExecutivesKey CompetitorsTerns PharmaceuticalsNASDAQ:TERNXOMANASDAQ:XOMAKamadaNASDAQ:KMDANeoleukin TherapeuticsNASDAQ:NLTXErascaNASDAQ:ERASView All CompetitorsInsiders & InstitutionsGSG Advisors LLCSold 12,000 shares on 4/11/2024Ownership: 0.068%Nomura Holdings Inc.Sold 4,980 shares on 3/27/2024Ownership: 5.376%Joseph TodiscoBought 13,561 shares on 3/13/2024Total: $50,718.14 ($3.74/share)Nomura Holdings Inc.Sold 4,980 shares on 2/14/2024Ownership: 5.376%Tower Research Capital LLC TRC Bought 10,695 shares on 2/13/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions CRMD Stock Analysis - Frequently Asked Questions Should I buy or sell CorMedix stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRMD shares. View CRMD analyst ratings or view top-rated stocks. What is CorMedix's stock price target for 2024? 4 equities research analysts have issued 1 year price objectives for CorMedix's shares. Their CRMD share price targets range from $9.00 to $19.00. On average, they expect the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 150.5% from the stock's current price. View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts. How have CRMD shares performed in 2024? CorMedix's stock was trading at $3.76 at the beginning of 2024. Since then, CRMD shares have increased by 38.0% and is now trading at $5.19. View the best growth stocks for 2024 here. Are investors shorting CorMedix? CorMedix saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 9,380,000 shares, an increase of 13.7% from the March 31st total of 8,250,000 shares. Based on an average trading volume of 587,000 shares, the short-interest ratio is currently 16.0 days. View CorMedix's Short Interest. When is CorMedix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CRMD earnings forecast. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) released its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. What ETFs hold CorMedix's stock? ETFs with the largest weight of CorMedix (NASDAQ:CRMD) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Invesco Nasdaq Future Gen 200 ETF (QQQS). When did CorMedix's stock split? Shares of CorMedix reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL). Who are CorMedix's major shareholders? CorMedix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include GSG Advisors LLC (0.07%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRMD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
